David W (@rn_flex) header
David W (@rn_flex) profile picture

Primary care NP, lover of glucagon agonism, incretin nerd, photographer, mountain lover, coonhound rescuer

Primary care land
Joined October 2021
10 tips about why Calcitonin is bad actually 🤣 This is my next Incretin Space article and it's 2600 words long and only about half way done 🙈🙈 so much old data to sift through and then match up to Elora/Cagri/Petrelintide
2
45
Replying to @bioinvestor24
This was the slide that surprised me. Biliary tract cancer is rare but just a death sentence. Small n but clear response.
2
234
Replying to @bioinvestor24
Like holy smokes.
2
6
1,637
Replying to @bioinvestor24
First trial I've ever seen with decreased appetite as a reason to stop the trial. Also the these two slides. Elora alone is a modest diabetes drug. Together it's super effective. And the % with normal BMI in just 48 weeks is 🤯
1
5
194
Pick Tirz, Elora or Reta and look at week 8! All of them are about ~7% average weight loss! Just meaningless marketing talk here from Novo. Most people respond quickly to these newer generation meds!
#PRESS Novo’s CagriSema analyses show 67.8% of people studied are early responders, achieving ≥5% weight loss by week 8.  Adults with overweight or obesity also reported  meaningful quality of life improvements in physical function. Learn more in the press release here: novonordisk.com/content/nnco…
2
1
14
2,055
I know we're on the same wavelength about this. Check out Survo. Huge DC rate due to rigid trial protocols. Nausea rate never gets above 10%!! Give Survo the same trial flexibility as CS & I bet the DC rate plummets. Having 30% nausea + 20% constipation a year into trial is wild
3
1
108
Don't need 100% weight loss with 200% nausea
2
68
Replying to @fdzmurillo
In a world where tirzepatide exists and low dose retatrutide exists this is solidly 3rd line or use only if insurance forces me to. My patients would not go for 60% nausea and a near guarantee of constipation or diarrhea. You're missing the forest for the trees
2
1,033
Cagrisema in Redefine 9...worse tolerability at lower doses than Survodutide and that's with more flexible titration. It's not as good for A1c as tirzepatide, and even the lower doses have over double the rate of SE/AE as tirzepatide. I can't see myself prescribing this often.
12
1
2
30
18,300
Launching a monoagonist GLP1 in probably 2029? In the face of *waves hand towards Eli Lilly's incretin pipeline* Bold move
4
262